Details of the Drug
General Information of Drug (ID: DMUW2EJ)
Drug Name |
1,2-Bis-(4-bromo-phenyl)-ethane-1,2-dione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
4,4'-Dibromobenzil; 35578-47-3; Ethanedione, bis(4-bromophenyl)-; p,p'-Dibromobenzil; 1,2-bis(4-bromophenyl)ethane-1,2-dione; Benzyl, 4,4'-dibromo-; UNII-O4TXV8A656; Bis(4-bromophenyl)ethanedione; 4,4'-Dibromodibenzoyl; O4TXV8A656; 1,2-Ethanedione, 1,2-bis(4-bromophenyl)-; NYCBYBDDECLFPE-UHFFFAOYSA-N; MFCD00000104; W-110862; NSC74075; EINECS 252-628-1; NSC 74075; Benzyl,4'-dibromo-; 4,4'-dibromo-benzil; ACMC-209ihu; AI3-25040; AC1L3WFW; 1,2-Bis-(4-bromo-phenyl)-ethane-1,2-dione; Benzil-based compound, 11; NCIOpen2_008898
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 368.02 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 4.8 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 3 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||